TABLE 1.
Univariate risk factors for severe keratinocyte dysplasia
| Controls N (%) |
Cases N (%) |
OR (95% CI) | P-value | |
|---|---|---|---|---|
| Gender | ||||
| Female | 31 (42%) | 17 (46%) | 1.0 | 0.67 |
| Male | 43 (58%) | 20 (54%) | 0.84 (0.4–1.9) | |
| Donor type | ||||
| Matched sib | 24 (32%) | 12 (32%) | [1.0] | 0.99 |
| Unrelated | 42 (57%) | 21 (57%) | 1.00 (0.4–2.5) | |
| Autologous | 4 (5%) | 2 (5%) | 1.00 (0.2–6.6) | |
| Other related | 4 (5%) | 2 (5%) | 1.00 (0.2–5.9) | |
| Diagnosis | ||||
| AML | 32 (43%) | 12 (32%) | [1.0] | 0.002 |
| CML | 9 (12%) | 2 (5%) | 0.58 (0.1–3.2) | |
| MDS | 17 (23%) | 21 (57%) | 3.16 (1.2–8.1) | |
| Other | 16 (22%) | 2 (5%) | 0.28 (0.1–1.4) | |
| Conditioning | ||||
| Busulfan in conditioning regimen | ||||
| No | 36 (49%) | 6 (16%) | 1.0 | 0.0002 |
| Yes | 38 (51%) | 31 (84%) | 7.25 (2.1–25) | |
| Cytoxan in conditioning regimen | ||||
| No | 22 (30%) | 5 (14%) | 1.0 | 0.02 |
| Yes | 52 (70%) | 32 (86%) | 4.21 (1.1–16) | |
| Fludarabine in conditioning regimen | ||||
| No | 54 (73%) | 34 (92%) | [1.0] | 0.004 |
| Yes | 20 (27%) | 3 (8%) | 0.15 (0.0–0.7) | |
| TBI in conditioning regimen | ||||
| None | 42 (57%) | 31 (42%) | 1.0 | 0.007 |
| 200 cGy | 16 (22%) | 2 (6%) | 0.14 (0.0–0.7) | |
| >200 cGy | 16 (22%) | 3 (8%) | 0.32 (0.1–1.2) | |
| Nonmyeloablative conditioning | ||||
| No | 58 (78%) | 35 (95%) | 1.0 | 0.009 |
| Yes | 16 (22%) | 2 (5%) | 0.16 (0.0–0.8) | |
| GVHD | ||||
| Clinical acute GHVD (Grade 2–4) | ||||
| No | 22 (30%) | 9 (24%) | 1.0 | 0.53 |
| Yes | 52 (70%) | 28 (76%) | 1.35 (0.5–3.4) | |
| Histological GVHD (Grade 2–4) | ||||
| No | 29 (39%) | 8 (22%) | 1.0 | 0.05 |
| Yes | 45 (61%) | 29 (78%) | 2.61 (1.0–7.0) | |